戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              ABH binds with high affinity to phosphatidylinositol-3-p
2                                              ABH(O) blood group polymorphisms are based on well-known
3  protein, with specificity for type 1 and 11 ABH blood group epitopes and polylactosamine glycan cont
4                                   Out of 397 ABHs, 55.7% evolved to a PBH.
5                          However, at pH 9.5, ABH and BEC are slow-binding inhibitors of the enzyme wi
6  inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) (K(d) = 11 microM).
7 nt standards, 2-amino-6-boronohexanoic acid (ABH) and N-hydroxy-nor-l-arginine (nor-NOHA).
8  analogues 2(S)-amino-6-boronohexanoic acid (ABH) and S-(2-boronoethyl)-L-cysteine (BEC), which are k
9 e analogue 2(S)-amino-6-boronohexanoic acid (ABH) binds as a tetrahedral boronate anion to Mn(2+)(2),
10 inhibitors 2(S)-amino-6-boronohexanoic acid (ABH, Kd = 5 nM) and S-(2-boronoethyl)-l-cysteine (BEC, K
11 e analogue 2(S)-amino-6-boronohexanoic acid (ABH, pH 7.0) and the catalytic product L-Orn (pH 7.0) de
12                A BH was considered as acute (ABH) when it occurred coincidently with the presence of
13 and their interacting fungi with pre-adapted ABH proteins, which were deployed for SL perception or r
14                                     Using an ABH-glycan microarray, we quantified ABO-A antigen-subty
15  PDs were associated with subsequent ABD and ABH loss (P <0.05 for each).
16 pths were associated with subsequent ABD and ABH loss (p<0.05 for each).
17 ne PD was associated with subsequent ABD and ABH loss.
18 ne PD was associated with subsequent ABD and ABH loss.
19 or glucose, total cholesterol, ALT, AST, and ABH data.
20 lamed eyes of B10R III, C57BL/6, BALB/c, and ABH Biozii mice were immunostained for APC markers (33D1
21 anges did not predict 2-year ABH changes and ABH/ABD changes, respectively.
22 ges did not predict two-year ABH changes and ABH/ABD changes, respectively.
23 nd competitive binding studies of CvGal1 and ABH-specific monoclonal antibodies with intact and degly
24 l therapy against liver-stage infection, and ABH may serve as a lead for the development of inhibitor
25    Oligosaccharides containing the Lewis and ABH antigenic epitopes were involved in binding.
26 ut strong selection for retention of RID and ABH suggests these two domains may primarily function by
27                             However, RID and ABH, which are naturally delivered together with ACD, bl
28 nic fungus Cryphonectria parasitica, another ABH named CpD14 was found to possess SL binding and hydr
29 ells of heart and spleen, only type II-based ABH antigens were expressed; type III/IV structures were
30                                Type II-based ABH were expressed on erythrocytes of all blood groups.
31  PD were positively associated with baseline ABH loss (P <0.0001), and baseline PDs were associated w
32  PD were positively associated with baseline ABH loss (p<0.0001) and baseline probing depths were ass
33                                      Because ABH antigen subtypes are expressed differently in variou
34                                      Because ABH binds as an analogue of the tetrahedral intermediate
35 s (NLVs) have various capacities for binding ABH histo-blood group antigens, suggesting that differen
36 n by sensitization to myelin antigens Biozzi ABH mice also develop spasticity and tremor.
37                              At pH 7.5, both ABH and BEC are classical, competitive inhibitors of hum
38 trate the inhibition of arginase activity by ABH in human and murine myeloid cells.
39 ously unstudied alpha-beta hydrolase domain (ABH) is shown here to activate CDC42, although the effec
40 n (RID), and an alpha/beta hydrolase domain (ABH)-to suppress innate immunity and enhance colonizatio
41 ts of anti-IL-17A in a chronic relapsing EAE ABH mouse model using conventional scoring, quantitative
42 istic, with 5% of A1 donors typing as either ABH high- or low-expressers.
43 pact of thin-walled structures with embedded ABHs and distributed dynamic vibration absorbers (DVAs)
44 ve experimental autoimmune encephalomyelitis ABH mouse model of multiple sclerosis using conventional
45                                 We evaluated ABH glycans within human pancreata, isolated islets, hES
46 o-matured islet-like clusters do not express ABH antigens.
47 s, endocrine and ductal cells do not express ABH antigens.
48 o-matured hESC-derived islets do not express ABH antigens.
49                            Platelets express ABH antigens, which can adversely effect platelet transf
50 issue within islet preparations that express ABH glycans.
51 protein that mediates binding to fucosylated ABH antigens of the ABO blood group.
52 idues as critical for binding to fucosylated ABH antigens.
53                                  Blood group ABH(O) carbohydrate antigens are carried by precursor st
54 bone density (ABD) and alveolar bone height (ABH) measurements.
55 bone density (ABD) and alveolar bone height (ABH) measurements.
56 eding index (GBI), and alveolar bone height (ABH).
57                 Angina bullosa hemorrhagica (ABH) describes benign subepithelial oral blood blisters
58 sis of beta-alkyl N-aryl aza Baylis-Hillman (ABH) adducts is reported.
59                     The acoustic black hole (ABH) structure exhibits remarkable energy focalization a
60 leton, the function of alpha-beta hydrolase (ABH) remained elusive.
61  the SL receptor is an alpha/beta-hydrolase (ABH) encoded by the DWARF14 (D14)/KARRIKIN INSENSITIVE2
62 resolution structure of the human arginase I-ABH complex yields an unprecedented view of the binuclea
63 e phase errors in genotypic data that are in ABH format.
64  qualitative and quantitative differences in ABH antigen expression between erythrocytes and vascular
65 o be used to correct linkage phase errors in ABH formatted datasets.
66 latelet transfusion recovery and survival in ABH-incompatible recipients.
67 he beta-position of the literature inhibitor ABH (1).
68 zed against chemically synthesized type I-IV ABH and related glycans.
69 ons do not affect the binding of monofucosyl ABH HBGAs but that they can modulate the binding strengt
70       Interestingly, antibodies to other non-ABH glycans, such as the alpha-Gal antigen, also correla
71 he host immune system of exposure to nonself ABH antigens during early life in human heart versus por
72 , IgG, and IgA isotype antibodies to nonself ABH subtypes were detected in control participants and r
73 allyl esters and carbonyl compounds to novel ABH adducts.
74       In a search for the molecular basis of ABH status of tumors as correlated with malignancy, we s
75 ng to P. marinus trophozoites, no binding of ABH blood group antibodies was observed.
76 ce the vibration attenuation capabilities of ABH structures within the low frequency range.
77 es encoding and regulating the expression of ABH and Lewis antigens in bodily secretions particularly
78      It is widely thought that expression of ABH antigens on platelets is insufficient to materially
79                                Expression of ABH in vivo reduces intracellular PtdIns3P levels and it
80 the clinical and histopathologic features of ABH which appeared after routine scaling and root planin
81                                  The odds of ABH loss were higher among sites with concurrent 1-year
82                                  The odds of ABH loss were higher among sites with concurrent one-yea
83    Little is known about the pathogenesis of ABH, although most cases have been associated with mild
84 is the first report highlighting the role of ABH in inhibiting autophagy and endosomal trafficking in
85 ficient to materially affect the survival of ABH-incompatible platelets in transfusion recipients, bu
86 ype II and/or B subtype II antigens-the only ABH antigen subtypes expressed in heart tissue-were abse
87                    Among A1 donors, platelet ABH varied significantly between donors (0%-87%).
88 wever, was minimal, suggesting that platelet ABH expression is a stable, donor-specific characteristi
89                                 Unlike RBCs, ABH expression on platelets may be determined primarily
90 ns to the underlying H(O) structure, we show ABH antigens stabilize sialylated glycan clusters on ery
91 (HV) virus-like particles (VLPs) to specific ABH histo-blood group antigens was investigated by using
92 her show that by stabilizing such structures ABH antigens can also modulate sialic acid-mediated inte
93                                   We studied ABH expression in 166 group A apheresis platelet donors
94                 This study demonstrates that ABH is an esterase/lipase with catalytic Ser-His-Asp tri
95                   Our data further show that ABH loading on VWF is also affected by ABO expresser phe
96                   We show in this study that ABH antigens found on human erythrocytes modulate the sp
97 ha(1,2)fucosyltransferase gene (FUT2) in the ABH histo-blood group family and did not express the H t
98 ; induction and control of spasticity in the ABH mouse model of multiple sclerosis; conditional delet
99 rcome the substrate scope limitations of the ABH reaction, which converts allyl esters and carbonyl c
100 itially, the focusing characteristics of the ABH thin-walled structure is analyzed, aiding in the att
101 of the C-domain of Gal-4 (Gal-4C) toward the ABH-carbohydrate histo-blood antigens with different cor
102                                        Thus, ABH antigens can noncovalently alter the presentation of
103  exhibit different patterns of attachment to ABH histo-blood group antigens, which are carbohydrate e
104 force, direct binding of lethal pathogens to ABH antigens has not been reported.
105  study comparing specific donor factors with ABH expression on platelet membranes and glycoconjugates
106 he P domain structure of a 2004 variant with ABH and secretor Lewis HBGAs and compared it with the pr
107 e able to block the interaction of VLPs with ABH histo-blood group antigens (HBGA), suggesting that m
108 into optimizing the integration of DVAs with ABHs in thin-walled structures for enhanced broadband vi
109 lative CAL/PD changes did not predict 2-year ABH changes and ABH/ABD changes, respectively.
110 ear RCAL/PD changes did not predict two-year ABH changes and ABH/ABD changes, respectively.
111 splantation continues to be ABO-matched, yet ABH antigen expression within isolated human islets or n

 
Page Top